Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis | BMJ Open Gastroenterology
Infliximab formulation strategy for a stable ileo-colonic targeted oral dosage form intended for the topical treatment of inflammatory bowel disease - ScienceDirect
Frontiers | Probiotics and Vitamin D/Vitamin D Receptor Pathway Interaction: Potential Therapeutic Implications in Inflammatory Bowel Disease | Pharmacology
Probiotics for maintenance of remission in ulcerative colitis - Naidoo, K - 2011 | Cochrane Library
Frontiers | Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring | Pharmacology
Advances in Clinical and Experimental Medicine
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus - Digestive and Liver Disease
Indicators of active disease and steroid dependency in patients with inflammatory bowel diseases not treated with biologics in a German real-world-setting | SpringerLink
Frontiers | Role of Eosinophils in Intestinal Inflammation and Fibrosis in Inflammatory Bowel Disease: An Overlooked Villain? | Immunology
The influence of cytokines on the complex pathology of ulcerative colitis - ScienceDirect
Frontiers | The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges | Immunology
Predictive factors of relapse after dose reduction of oral 5-aminosalicylic acid in patients with ulcerative colitis in the remi
Frontiers | Relationship Between Patient Sex and Serum Tumor Necrosis Factor Antagonist Drug and Anti-drug Antibody Concentrations in Inflammatory Bowel Disease; A Nationwide Cohort Study | Medicine
Cureus | Patterns of Complementary and Alternative Medicine Use in Saudi Arabian Patients With Inflammatory Bowel Disease: A Cross-Sectional Study
Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis | BMJ Open Gastroenterology
PDF) Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases
Frontiers | Exploring the Mechanism of Indigo Naturalis in the Treatment of Ulcerative Colitis Based on TLR4/MyD88/NF-κB Signaling Pathway and Gut Microbiota | Pharmacology
PDF) Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal Inflammation and Disease Activity in Ulcerative Colitis
Has infliximab influenced the course and prognosis of acute severe ulc | BTT
Rate of Adverse Events and Associated Health Care Costs for the Management of Inflammatory Bowel Disease in Germany - Clinical Therapeutics
Cureus | Prediction of Mucosal Health by NLR, CRP x NLR and MPV in Ulcerative Colitis: Can Their Availability Change According to Treatment Options?
Frontiers | Combination Immunotherapy Use and Withdrawal in Pediatric Inflammatory Bowel Disease—A Review of the Evidence | Pediatrics
Frontiers | The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potential Therapeutic Strategies | Medicine
KoreaMed Synapse
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement | Annals of the Rheumatic Diseases
Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial
